Previously doing business as Kura Therapeutics, Nurix is an early-stage biotechnology company with a novel allosteric drug discovery platform which offers unique inroads to previously intractable targets. The firm's current focus is on the discovery and development of kinase inhibitors for inflammatory disease and modulators of ubiquitin ligases for a broad range of human disorders. Nurix, Inc. is involved in the discovery and developiment of therapies that modulate the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology.
